MiNK Therapeutics (INKT) reached a partnership agreement with C-Further, a pediatric oncology consortium. They are receiving about $1.1 million in non-dilutive funding to develop an off-the-shelf cell therapy for pediatric cancers targeting the PRAME antigen. The deal includes a double-digit share of potential future commercial revenue for MiNK. The agreement is non-exclusive, so the company keeps the rights to use its platform for other projects. Researchers at the University of Southampton will handle the preclinical studies to prep the therapy for human trials.